Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...
INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More
INHIBIKASE THERAPEUTICS ($IKT) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting ...
Hosted on MSN23d
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowA downtrend has been apparent in Inhibikase Therapeutics, Inc. (IKT) lately. While the stock has lost 15.4% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was ...
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two ...
BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...
Inhibikase Therapeutics (IKT) announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., former CMO of Arena Pharmaceuticals and CEO of CorHepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback